Skip to content
10-Q

Quarterly Report

Jazz Pharmaceuticals plc JAZZ

0001232524-26-000025

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 28, 2026 62.74M sh
Shares Diluted Q1 2026 · Mar 31, 2026 66.1M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 61M sh
Capex Q1 2026 · Mar 31, 2026 $19.7M
Capex restated Q1 2026 · Mar 31, 2025 $13.9M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $408.2M
Operating Cash Flow restated Q1 2026 · Mar 31, 2025 $429.8M
Long Term Debt Q1 2026 · Mar 31, 2026 $4.32B
Long Term Debt Q1 2026 · Dec 31, 2025 $4.33B
Short Term Debt Q1 2026 · Mar 31, 2026 $1.03B
Short Term Debt Q1 2026 · Dec 31, 2025 $1.03B
Cash And Equivalents Q1 2026 · Mar 31, 2026 $1.84B
Cash And Equivalents Q1 2026 · Dec 31, 2025 $1.39B
Stockholders Equity Q1 2026 · Mar 31, 2026 $4.53B
Stockholders Equity Q1 2026 · Dec 31, 2025 $4.32B
Stockholders Equity restated Q1 2026 · Mar 31, 2025 $4.17B
Stockholders Equity restated Q1 2026 · Dec 31, 2024 $4.09B
Current Liabilities Q1 2026 · Mar 31, 2026 $2.25B
Current Liabilities Q1 2026 · Dec 31, 2025 $2.24B
Current Assets Q1 2026 · Mar 31, 2026 $4.58B
Current Assets Q1 2026 · Dec 31, 2025 $4.17B
Total Assets Q1 2026 · Mar 31, 2026 $11.86B
Total Assets Q1 2026 · Dec 31, 2025 $11.66B
Eps Diluted Q1 2026 · Mar 31, 2026 $4.43
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.52
Eps Basic Q1 2026 · Mar 31, 2026 $4.73
Eps Basic Q1 2026 · Mar 31, 2025 −$1.52
Sga Expense Q1 2026 · Mar 31, 2026 $352.7M
Sga Expense restated Q1 2026 · Mar 31, 2025 $514M
Net Income Q1 2026 · Mar 31, 2026 $293.1M
Net Income restated Q1 2026 · Mar 31, 2025 −$92.5M
Operating Income Q1 2026 · Mar 31, 2026 $336.6M
Operating Income restated Q1 2026 · Mar 31, 2025 −$55.9M
Revenue Q1 2026 · Mar 31, 2026 $1.07B
Revenue restated Q1 2026 · Mar 31, 2025 $897.8M